Symptoms of Schizophrenia, Archives of General Psychiatry, vol.52, issue.5, pp.341-51, 1995. ,
DOI : 10.1001/archpsyc.1995.03950170015003
Chronic Restlessness With Antipsychotics, American Journal of Psychiatry, vol.164, issue.11, pp.1648-54, 2007. ,
DOI : 10.1176/appi.ajp.2007.07071150
Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder, Archives of General Psychiatry, vol.56, issue.3, p.241, 1999. ,
DOI : 10.1001/archpsyc.56.3.241
Histoire des Neuroleptiques d'action prolong??e, L'Enc??phale, vol.34, pp.226-257, 2008. ,
DOI : 10.1016/S0013-7006(08)75519-2
Serum Levels of Risperidone and Its Metabolite, 9-Hydroxyrisperidone: Correlation Between Drug Concentration and Clinical Response, Therapeutic Drug Monitoring, vol.31, issue.4, pp.475-81, 2009. ,
DOI : 10.1097/FTD.0b013e3181aa4780
Biochemical profile of risperidone, a new antipsychotic, J Pharmacol Exp Ther. nov, vol.247, issue.2, pp.661-70, 1988. ,
Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties, J Pharmacol Exp Ther. févr, vol.244, issue.2, pp.685-93, 1988. ,
Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin???dopamine hypothesis, In: Progress in Brain Research [Internet], 2008. ,
DOI : 10.1016/S0079-6123(08)00910-2
Pharmacokinetic profile of long-acting injectable risperidone at steady-state : comparison with oral administration, L'Enc??phale, vol.31, issue.5, pp.609-624, 2005. ,
DOI : 10.1016/S0013-7006(05)82420-0
Determination of risperidone in human plasma by HPLC-MS/MS and its application to a pharmacokinetic study in Chinese volunteers, Journal of Zhejiang University SCIENCE B, vol.9, issue.2, pp.114-134, 2008. ,
DOI : 10.1631/jzus.B0710439
Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers, Int. Journal of Clinical Pharmacology and Therapeutics, vol.47, issue.02, pp.124-155, 2009. ,
DOI : 10.5414/CPP47124
Intra- and Interindividual Variations in Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients Treated Chronically with Various Doses of Risperidone, Therapeutic Drug Monitoring, vol.25, issue.6, pp.657-64, 2003. ,
DOI : 10.1097/00007691-200312000-00003
Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity, J Clin Psychiatry. mai, vol.55, pp.5-12, 1994. ,
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication, Acta Psychiatrica Scandinavica, vol.156, issue.1, pp.21-27, 2006. ,
DOI : 10.1016/j.eurpsy.2003.11.007
Clinical Significance of a CYP2D6 Poor Metabolizer -A Patient With Schizophrenia on Risperidone Treatment, Therapeutic Drug Monitoring, vol.30, issue.6, pp.748-51, 2008. ,
DOI : 10.1097/FTD.0b013e3181896afc
Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients, Journal of Clinical Psychopharmacology, vol.29, issue.3, pp.272-279, 2009. ,
DOI : 10.1097/JCP.0b013e3181a289e0
The Pharmacokinetics of Paliperidone Versus Risperidone, Psychosomatics, vol.51, issue.1, pp.80-88, 2010. ,
DOI : 10.1016/S0033-3182(10)70664-2
CYP450 Pharmacogenetic treatment strategies for antipsychotics: A review of the evidence, Schizophrenia Research, vol.149, issue.1-3, pp.1-14, 2013. ,
DOI : 10.1016/j.schres.2013.06.035
Interactions between the cytochrome P450 system and the secondgeneration antipsychotics, J Psychiatry Neurosci JPN. mars, vol.28, issue.2, pp.99-112, 2003. ,
Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication With Carbamazepine or Valproate, Therapeutic Drug Monitoring, vol.22, issue.4, pp.481-486, 2000. ,
DOI : 10.1097/00007691-200008000-00019
Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes, Drug Metab Dispos Biol Fate Chem. oct, vol.29, issue.10, pp.1263-1271, 2001. ,
Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples, Journal of Psychopharmacology, vol.39, issue.7, pp.616-644, 2013. ,
DOI : 10.1037/0022-3514.54.6.1020
Side effect profiles of new antipsychotic agents, J Clin Psychiatry, vol.57, issue.11, pp.40-45, 1996. ,
Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies, Schizophrenia Research, vol.183, pp.10-21, 2017. ,
DOI : 10.1016/j.schres.2016.11.010
Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone11This work was sponsored by Eli Lilly and Company., Psychoneuroendocrinology, vol.28, issue.2, pp.55-68, 2003. ,
DOI : 10.1016/S0306-4530(02)00127-0
Hyperprolactinemia and sexual function in men: a short review, International Journal of Impotence Research, vol.353, issue.Suppl 1, pp.373-380, 2003. ,
DOI : 10.1016/S0140-6736(05)74947-3
SEXUAL DYSFUNCTION IN WOMEN WITH HYPERPROLACTINEMIA: A PILOT STUDY REPORT, The Journal of Urology, vol.174, issue.5, pp.1921-1926, 2005. ,
DOI : 10.1097/01.ju.0000176456.50491.51
Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone, Neuropsychiatric Disease and Treatment, vol.5, pp.47-54, 2009. ,
DOI : 10.2147/NDT.S4766
Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy], Neuropsychiatr Klin Diagn Ther Rehabil Organ Ges Osterreichischer Nervenarzte Psychiater, vol.23, issue.2, pp.71-83, 2009. ,
Antipsychotic-Induced Hyperprolactinemia, Pharmacotherapy, vol.89, issue.1, pp.64-73, 2009. ,
DOI : 10.1016/j.schres.2004.12.004
Antipsychotic-induced weight gain: a review of the literature, J Clin Psychiatry, vol.62, pp.22-31, 2001. ,
Diab??te et antipsychotiques de seconde g??n??ration, Annales d'Endocrinologie, vol.70, issue.4, pp.202-212, 2009. ,
DOI : 10.1016/j.ando.2009.07.003
Priapism associated with atypical antipsychotic medications: a review, International Clinical Psychopharmacology, vol.23, issue.1, pp.9-17, 2008. ,
DOI : 10.1097/YIC.0b013e3282f1c1ef
QTc Prolongation: Possible Association With Risperidone and/or Haloperidol, Psychosomatics, vol.44, issue.6, p.521, 2003. ,
DOI : 10.1176/appi.psy.44.6.521
Risperidone-Induced Sialorrhea, Psychosomatics, vol.42, issue.3, p.276, 2001. ,
DOI : 10.1176/appi.psy.42.3.276
Antipsychotiques atypiques et syndrome malin des neuroleptiques??: br??ve revue de la litt??rature, L'Enc??phale, vol.34, issue.6, pp.618-642, 2008. ,
DOI : 10.1016/j.encep.2007.11.007
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study, European Neuropsychopharmacology, vol.10, issue.1, pp.51-58, 1999. ,
DOI : 10.1016/S0924-977X(99)00054-1
Pharmacokinetic and Safety Assessments of Galantamine and Risperidone after the Two Drugs Are Administered Alone and Together, The Journal of Clinical Pharmacology, vol.314, issue.7076, pp.1341-51, 2002. ,
DOI : 10.1136/bmj.314.7076.266
Pharmacokinetics and Safety of Combination Therapy with Lithium and Risperidone, Pharmacopsychiatry, vol.39, issue.6, pp.230-231, 2006. ,
DOI : 10.1055/s-2006-950394
Effect of Topiramate on Plasma Concentrations of Clozapine, Olanzapine, Risperidone, and Quetiapine in Patients With Psychotic Disorders, Clinical Neuropharmacology, vol.30, issue.2, pp.107-120, 2007. ,
DOI : 10.1097/01.wnf.0000240955.49315.65
Carbamazepine???Risperidone Interactions in Patients With Epilepsy, Clinical Neuropharmacology, vol.25, issue.2, pp.97-100, 2002. ,
DOI : 10.1097/00002826-200203000-00007
Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia, Pharmacological Research, vol.52, issue.6, pp.497-501, 2005. ,
DOI : 10.1016/j.phrs.2005.09.005
Plasma Risperidone Concentrations During Combined Treatment with Sertraline, Therapeutic Drug Monitoring, vol.26, issue.4, pp.386-90, 2004. ,
DOI : 10.1097/00007691-200408000-00008
Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: A Clinically Relevant Pharmacokinetic Drug Interaction, Journal of Clinical Psychopharmacology, vol.22, issue.4, pp.419-442, 2002. ,
DOI : 10.1097/00004714-200208000-00014
Dose-Dependent Interaction of Paroxetine With Risperidone in Schizophrenic Patients, Journal of Clinical Psychopharmacology, vol.25, issue.6, pp.527-559, 2005. ,
DOI : 10.1097/01.jcp.0000185428.02430.c7
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine, European Journal of Clinical Pharmacology, vol.51, issue.1, pp.73-81, 1996. ,
DOI : 10.1007/s002280050163
Effect of venlafaxine on the pharmacokinetics of risperidone, J Clin Pharmacol. mars, vol.39, issue.3, pp.297-309, 1999. ,
A Case of Delayed NMS Induced by Risperidone, Psychiatric Services, vol.51, issue.2, pp.254-259, 2000. ,
DOI : 10.1176/appi.ps.51.2.254-a
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients, Clinical Pharmacology & Therapeutics, vol.78, issue.5, pp.520-528, 2005. ,
DOI : 10.1016/j.clpt.2005.07.007
P-glycoprotein and cytochrome P450 3A4 involvement in risperidone transport using an in vitro Caco-2/TC7 model and an in vivo model, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.31, issue.4, pp.878-86, 2007. ,
DOI : 10.1016/j.pnpbp.2007.01.028
Valproic Acid improves Psychotic Agitation without Influencing Plasma Risperidone Levels in Schizophrenic Patients, Pharmacopsychiatry, vol.40, issue.1, pp.9-13, 2007. ,
DOI : 10.1055/s-2007-958521
Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine, Epilepsia, vol.29, issue.5, pp.771-775, 2005. ,
DOI : 10.1358/dot.2003.39.7.799445
Effect of Rifampin, an Inducer of CYP3A and P-glycoprotein, on the Pharmacokinetics of Risperidone, The Journal of Clinical Pharmacology, vol.45, issue.1, pp.66-72, 2008. ,
DOI : 10.1046/j.1365-2125.1998.t01-1-00698.x
Little Effects of Low Dosage of Levomepromazine on Plasma Risperidone Levels, Pharmacopsychiatry, vol.38, issue.2, pp.98-100, 2005. ,
DOI : 10.1055/s-2005-837811
Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses, British Journal of Clinical Pharmacology, vol.92, issue.s1, pp.50-57, 2004. ,
DOI : 10.1038/clpt.1993.146
Effect of Adjunctive Lamotrigine Treatment on the Plasma Concentrations of Clozapine, Risperidone and Olanzapine in Patients With Schizophrenia or Bipolar Disorder, Therapeutic Drug Monitoring, vol.28, issue.5, pp.599-602, 2006. ,
DOI : 10.1097/01.ftd.0000246763.59506.b0
Serum concentrations of paliperidone versus risperidone and clinical effects, European Journal of Clinical Pharmacology, vol.163, issue.3, pp.797-803, 2010. ,
DOI : 10.1176/ajp.156.6.869
URL : https://hal.archives-ouvertes.fr/hal-00582164
Comparative Pharmacology of Risperidone and Paliperidone, Drugs in R&D, vol.103, issue.6, pp.163-74, 2015. ,
DOI : 10.1016/S0091-6749(99)70174-0
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study, The International Journal of Neuropsychopharmacology, vol.13, issue.05, pp.635-682, 2010. ,
DOI : 10.1017/S1461145709990988
Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia, Clinical Pharmacokinetics, vol.3, issue.2, pp.585-600, 2009. ,
DOI : 10.1248/cpb.29.1410
Paliperidone for schizophrenia. Am J Health-Syst Pharm AJHP Off J Am Soc Health-Syst Pharm. 1 mars, pp.403-416, 2008. ,
Conclusion, Hormone Molecular Biology and Clinical Investigation, vol.61, issue.0, 2017. ,
DOI : 10.1515/hmbci-2017-0004
Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice, Annals of General Psychiatry, vol.13, issue.1, p.10, 2014. ,
DOI : 10.1017/S1461145709990988
Dosing and Switching Strategies for Paliperidone Palmitate, CNS Drugs, vol.25, issue.10, pp.829-874, 2011. ,
DOI : 10.2165/11591690-000000000-00000
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update, Pharmacopsychiatry. sept, vol.44, issue.06, pp.195-235, 2011. ,
Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology, Current Drug Delivery, vol.13, issue.3, pp.353-61, 2016. ,
DOI : 10.2174/1567201812666151029100909
Risperidone plasma levels, clinical response and side???effects, European Archives of Psychiatry and Clinical Neuroscience, vol.7, issue.4, pp.261-269, 2005. ,
DOI : 10.4088/JCP.v60n0801
Therapeutic Drug Monitoring of Risperidone Using a New, Rapid HPLC Method: Reappraisal of Interindividual Variability Factors, Therapeutic Drug Monitoring, vol.21, issue.1, pp.105-120, 1999. ,
DOI : 10.1097/00007691-199902000-00017
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite, Human Psychopharmacology: Clinical and Experimental, vol.185, issue.8, pp.529-561, 2006. ,
DOI : 10.1002/hup.811
Risperidone Drug Monitoring, Clinical Drug Investigation, vol.21, issue.2, pp.283-92, 2000. ,
DOI : 10.2165/00044011-200019040-00006
The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry, Pharmacopsychiatry, vol.37, issue.6, pp.243-65, 2004. ,
DOI : 10.1055/s-2004-832687
Determination of risperidone and 9-hydroxyrisperidone in plasma, urine and animal tissues by high-performance liquid chromatography, Journal of Chromatography B: Biomedical Sciences and Applications, vol.583, issue.2, pp.223-253, 1992. ,
DOI : 10.1016/0378-4347(92)80556-6
Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs, Journal of Chromatography B: Biomedical Sciences and Applications, vol.698, issue.1-2, pp.209-225, 1997. ,
DOI : 10.1016/S0378-4347(97)00302-2
Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia, Journal of Pharmaceutical and Biomedical Analysis, vol.19, issue.3-4, pp.595-601, 1999. ,
DOI : 10.1016/S0731-7085(98)00261-1
Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection, Journal of Chromatography B: Biomedical Sciences and Applications, vol.746, issue.2, pp.173-81, 2000. ,
DOI : 10.1016/S0378-4347(00)00323-6
Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in plasma after overdose, Journal of Chromatography B, vol.772, issue.2, pp.373-381, 2002. ,
DOI : 10.1016/S1570-0232(02)00091-0
Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring, Journal of Chromatography B, vol.794, issue.1, pp.35-47, 2003. ,
DOI : 10.1016/S1570-0232(03)00393-3
Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions, Journal of Chromatography B, vol.783, issue.1, pp.213-222, 2003. ,
DOI : 10.1016/S1570-0232(02)00661-X
Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma, Rapid Communications in Mass Spectrometry, vol.11, issue.6, pp.920-928, 2007. ,
DOI : 10.1001/archpsyc.1992.01820050018002
Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders, Biomedical Chromatography, vol.583, issue.9, pp.929-963, 2009. ,
DOI : 10.1002/bmc.1204
The pharmacological role and clinical applications of antipsychotics' active metabolites: paliperidone versus risperidone, Clin Exp Pharmacol. 1 janv, vol.3, 2013. ,
Effect of Obesity on the Pharmacokinetics of Drugs in Humans, Clinical Pharmacokinetics, vol.16, issue.5 Pt 1, pp.71-87, 2010. ,
DOI : 10.1097/01.AOG.0000149155.11912.52
Dosing in Obesity: A Simple Solution to a Big Problem, Clinical Pharmacology & Therapeutics, vol.61, issue.5, pp.505-513, 2007. ,
DOI : 10.1038/sj.clpt.6100381
Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies, J Clin Psychiatry, vol.64, pp.34-40, 2003. ,
Partial Compliance and Patient Consequences in Schizophrenia, The Journal of Clinical Psychiatry, vol.64, issue.11, pp.1308-1323, 2003. ,
DOI : 10.4088/JCP.v64n1105
The case for long-acting antipsychotic agents in the post-CATIE era, Acta Psychiatrica Scandinavica, vol.65, issue.5, pp.260-267, 2007. ,
DOI : 10.1111/j.1600-0447.2006.00766.x
Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness, J Clin Psychiatry. juin, vol.52, pp.23-33, 1991. ,
Cost-Effectiveness of Therapeutic Drug Monitoring, Therapeutic Drug Monitoring, vol.27, issue.1, pp.10-17, 2005. ,
DOI : 10.1097/00007691-200502000-00004